Sec Form 3 Filing - Temasek Holdings (Private) Ltd @ Akili, Inc. - 2022-08-19

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Temasek Holdings (Private) Ltd 2. Issuer Name and Ticker or Trading Symbol Akili, Inc. [ AKLI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 60B ORCHARD ROAD, #06-18 TOWER, 2, THE ATRIUM@ORCHARD 3. Date of Earliest Transaction (MM/DD/YY) 08/19/2022 (Street) SINGAPORE, U0238891 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10,336,425 I( 1 ) See Footnote( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Earnout Shares ( 2 )( 3 ) ( 2 )( 3 ) 08/19/2027 Common Stock 1,172,697 I( 1 ) See Footnote( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Temasek Holdings (Private) Ltd 60B ORCHARD ROAD, #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE, U0238891 X TLS Beta Pte. Ltd. 60B ORCHARD ROAD, #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE, U0238891 X Temasek Life Sciences Private Ltd 60B ORCHARD ROAD, #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE, U0238891 X Fullerton Management Pte Ltd 60B ORCHARD ROAD, #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE, U0238891 X Signatures TLS Beta Pte. Ltd., By: /s/ Zahedah Abdul Rashid, Director 08/26/2022 Signature of Reporting Person Date Temasek Life Sciences Private Limited, By: /s/ Lim Siew Lee Sherlyn, Director 08/26/2022 Signature of Reporting Person Date Fullerton Management Pte Ltd, By: /s/ Gregory Tan, Director 08/26/2022 Signature of Reporting Person Date Temasek Holdings (Private) Limited, By: /s/ Jason Norman Lee, Authorized Signatory 08/26/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The securities reported herein are directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temsaek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities directly owned by TLS Beta. ( 2 )Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022 (the "Merger Agreement"), by and among Social Capital Suvretta Holdings Corp. I, a Cayman Islands exempted company with limited liability ("SCS"), Karibu Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of SCS, and Akili Interactive Labs, Inc., a Delaware corporation. The Earnout Shares are subject to release from escrow to TLS Beta in three equal tranches upon the daily volume weighted average price of a share of the Issuer's common stock reaching $15.00/share, $20.00/share and $30.00/share, respectively, over any 20 trading days within any 30 consecutive trading day period following August 19, 2022 and prior to August 19, 2027, in each case, on the terms set forth in the Merger Agreement. ( 3 )(Continued from footnote 2) Before the Earnout Shares are released, such shares: (i) entitle TLS Beta to the rights of the holders of shares of the Issuer's common stock, including the right to vote or to receive dividends, distributions or other payment of any kind in respect of such Earnout Shares; (ii) will not bear interest; and (iii) are not assignable or transferable, except by operation of law, will or intestacy.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.